X4 Pharmaceuticals, Inc
XFOR · XNASCIK 1501697fmd_0CE28KA2SY3WVMCZE8GPBXGHT8Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2016 to Sep 30, 2026, 40 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 0 | 0 | 3 | 0 | 0 | 0 | 3 | 7 |
| Cost of revenue | – | – | – | – | – | – | 0 | 0 | 1 | 6 |
| Gross profit | – | – | – | – | – | – | 0 | 0 | 2 | 1 |
| Research and development | 18 | 17 | 20 | 30 | 42 | 51 | 61 | 72 | 82 | 73 |
| Total operating expenses | 24 | 22 | 29 | 52 | 63 | 85 | 88 | 108 | – | – |
| Operating income | (24) | (22) | (29) | (52) | (60) | (85) | (88) | (108) | (36) | (87) |
| Interest expense | 3 | 0 | 1 | 2 | 3 | 4 | 4 | 6 | 9 | 9 |
| Interest and investment income | – | 0 | 0 | 1 | 0 | 0 | 0 | 5 | 6 | 5 |
| Other non-operating income (expense) | 1 | 0 | (4) | (1) | (2) | (4) | (6) | 6 | (1) | 8 |
| Income before taxes | (23) | (22) | (33) | (53) | (62) | (89) | (94) | (101) | (37) | (79) |
| Income tax expense | – | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | (33) | (53) | (62) | (89) | (94) | (101) | (37) | (79) |
| Net income | (23) | (22) | (33) | (53) | (62) | (89) | (94) | (101) | (37) | (79) |
| Net income to common shareholders | (23) | (25) | (36) | (53) | (62) | (103) | (96) | (101) | (37) | – |